🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Showing page 25 of 857 · Phase 3 first, then by program name

  1. BAY94-9027

    Bayer HealthCare AG

    Hemophilia A

    phase 3 mab completed

    1 trial

  2. BCG (Tokyo 172) vaccine

    United Therapeutics Europe Ltd

    Tuberculosis Infection

    phase 3 mab terminated

    1 trial

  3. BCG VACCINE , JNJ-63723283, JNJ-17000139, JNJ-63723283

    Janssen-Cilag International N.V.

    High-Risk Non-muscle-invasive Bladder Cancer

    phase 3 small molecule active

    1 trial

  4. BCX4161

    Biocryst

    Hereditary Angioedema

    phase 3 small molecule completed

    4 trials

  5. BCX7353

    Biocryst

    Hereditary Angioedema

    phase 3 small molecule completed

    4 trials

  6. BCX7353 capsules

    Biocryst

    Hereditary Angioedema, HAE

    phase 3 small molecule completed

    1 trial

  7. BCX7353 capsules

    Biocryst

    Hereditary Angioedema

    phase 3 small molecule completed

    1 trial

  8. BDP

    Teva Pharma GmbH

    Allergic Rhinitis

    phase 3 small molecule completed

    1 trial

  9. BDP HFA

    Teva Pharma GmbH

    Seasonal Allergic Rhinitis

    phase 3 small molecule completed

    1 trial

  10. BDP Nasal Aerosol

    Teva Pharma GmbH

    Allergic Rhinitis

    phase 3 small molecule completed

    1 trial

  11. BE1116

    CSL Behring GmbH

    Complex Cardiovascular Surgery With Cardiopulmonary Bypass

    phase 3 mab active

    1 trial

  12. BEFIZAL L.P. 400 mg, comprimé enrobé à libération prolongée, BEZAFIBRATE LP 400 mg, BEFIZAL 200 mg, comprimé pelliculé, Placebo BEZAFIBRATE 200 mg

    Pari Pharma GmbH

    Subjects with PBC with a non-optimal response to UDCA.

    phase 3 small molecule active

    1 trial

  13. BEFIZAL L.P. 400 mg, comprimé enrobé à libération prolongée, placebo of bezafibrate

    Pari Pharma GmbH

    primary sclerosing cholangitis

    phase 3 small molecule active

    1 trial

  14. BELZUPACAP SAROTALOCAN, Placebo (Sham injection) to Belzupacap Sarotalocan solution for sham injection 0.0 mg/mL, BELZUPACAP SAROTALOCAN

    Aura Biosciences

    Primary Indeterminate Lesions or Small Choroidal Melanoma

    phase 3 small molecule active

    1 trial

  15. BENDAFOLIN 10 mg/ml Injektionslösung, Irinotecan Bendalis 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, 5-FLUOROURACIL–EBEWE, 50 MG/ML, ROZTWÓR DO WSTRZYKIWAN I INFUZJI, Napabucasin

    The George Institute

    Histologically confirmed adenocarcinoma of the colon or rectum that is metastatic.

    phase 3 small molecule active

    1 trial

  16. BENDAMUSTINE , TOCILIZUMAB , SILTUXIMAB , GEMCITABINE , ANAKINRA , Epcoritamab, DIPHENHYDRAMINE , PARACETAMOL , DEXAMETHASONE , RITUXIMAB , OXALIPLATIN , Epcoritamab

    Genmab A/S

    B-cell Lymphoma

    phase 3 small molecule active

    1 trial

  17. BENDAMUSTINE HYDROCHLORIDE, PREDNISOLONE , CYCLOPHOSPHAMIDE, LENALIDOMIDE, PREDNISONE, DOXORUBICIN HYDROCHLORIDE, Golcadomide, Golcadomide, PEGFILGRASTIM, Golcadomide, BENDAMUSTINE HYDROCHLORIDE, RITUXIMAB, LENALIDOMIDE, RITUXIMAB, VINCRISTINE SULFATE, LENALIDOMIDE, LENALIDOMIDE, CYCLOPHOSPHAMIDE, Golcadomide, DOXORUBICIN HYDROCHLORIDE

    Celgene Europe Limited

    Relapsed/Refractory Follicular Lymphoma

    phase 3 small molecule active

    1 trial

  18. BEP(500)

    United Therapeutics Europe Ltd

    Stage I Testicular Non-Seminomatous Germ Cell Tumor

    phase 3 small molecule completed

    1 trial

  19. BETAMETHASONE, Placebo of fludrocortisone, HYDROCORTISONE HEMISUCCINATE, Placebo of hydrocortisone, FLUDROCORTISONE

    Pari Pharma GmbH

    Patients admitted to the ICU proven or suspected infection as the main diagnosis.

    phase 3 small molecule active

    1 trial

  20. BEVACIZUMAB, BEVACIZUMAB, Lonsurf 20 mg/8.19 mg film-coated tablets, Telisotuzumab adizutecan, Lonsurf 15 mg/6.14 mg film-coated tablets

    AbbVie Deutschland GmbH & Co. KG

    Metastatic Colorectal Cancer

    phase 3 small molecule active

    1 trial

  21. BEVACIZUMAB, ERLOTINIB

    Fondazione Telethon ETS

    Non-squamous Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  22. BEVACIZUMAB, OXALIPLATIN, CALCIUM FOLINATE, FLUOROURACIL, PF-08634404

    Pfizer Australia Pty Ltd

    Metastatic Colorectal Cancer

    phase 3 small molecule active

    1 trial

  23. BEVACIZUMAB, PARACETAMOL , MK-2870, DEXAMETHASONE, BEVACIZUMAB , -, -, MK-2870, -

    Merck Sharp and Dohme

    Ovarian cancer recurrent

    phase 3 small molecule active

    1 trial

  24. BG00012

    Biogen

    Relapsing-Remitting Multiple Sclerosis

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources